The European Commission has approved Sanofi and Regeneron’s Dupixent for the treatment of moderate-to-severe chronic spontaneous urticaria.

Marks Breyanzi’s fourth indication in Europe, adding to existing approvals for several aggressive B-cell lymphomas.

BioMed X has launched a new collaborative research project with AbbVie, hosted at the BioMed X Institute in New Haven, ...

The Future of Oral Solids explores how innovation, advanced manufacturing, and integrated CDMO partnerships are reshaping the ...

AstraZeneca is investing $2 billion to expand its long-standing manufacturing footprint in Maryland. This includes an ...

Alex Mitchell, Vice President, Operations, Sentry BioPharma Services, discusses the growing use of FTZs by pharmaceutical ...

AGC Biologics has entered a new manufacturing agreement with AAVantgarde, marking AGC Biologics’ latest advancement in the ...

Novartis is expanding its operations in North Carolina, creating a new flagship manufacturing hub with end-to-end ...

David Basile of Hovione discusses expanded spray drying capacity in East Windsor and the benefits of integrated development, ...

Agreements will utilize ProFound's and Quotient's platform technologies to discover and validate novel treatments for respiratory and liver diseases.

Piramal Pharma Solutions' Grangemouth, UK facility has received updated MHRA GMP certificates following a successful compliance report and desktop inspection.

A conversation with Upperton’s Director of Pharmaceutical Sciences, Laura Mason about the upcoming trends she sees emerging ...